Breast reconstruction – Inflammatory breast cancer
Nipple-sparing mastectomy and areolar-sparing mastectomy are not recommended in inflammatory breast cancer or where the cancer involves the nipple/areolar complex.
SSM or NSM with immediate breast reconstruction can be offered to women at high risk for breast cancer (>25% lifetime risk) undergoing prophylactic mastectomy and women with known DCIS. SSM or NSM with immediate breast reconstruction is a reasonable option for women with early breast cancer who are believed to be likely lymph node negative. SSM, NSM, and ASM are not recommended for women intending to receive post-operative radiation with: • early breast cancer who are lymph node positive, inflammatory breast cancer or locally advanced breast cancer who will require postoperative RT. • any clinical skin or nipple-areolar complex (NAC) involvement by invasive tumour. NSM and ASM are not recommended for women with Paget disease of the breast or women with a retroareolar tumour.
How this guidance was developed
This recommendation was adapted from the CCO 2016 guidelines (Canada). The source recommendation was based on a systematic review of the evidence conducted to 13 May 2014 and was not graded by the source guideline authors. The source recommendation was adapted by removing ‘skin-sparing mastectomy’ as an intervention and removing 'inflammatory breast cancer or locally advanced breast cancer who will require postoperative radiation therapy' from the description of the patient population.
Breast reconstruction – Inflammatory breast cancer
Nipple-sparing mastectomy and areolar-sparing mastectomy are not recommended in inflammatory breast cancer or where the cancer involves the nipple/areolar complex.
This recommendation was adapted from the CCO 2016 guidelines (Canada). The source recommendation was based on a systematic review of the evidence conducted to 13 May 2014 and was not graded by the source guideline authors. The source recommendation was adapted by removing ‘skin-sparing mastectomy’ as an intervention and removing 'inflammatory breast cancer or locally advanced breast cancer who will require postoperative radiation therapy' from the description of the patient population.